Phase 1 Clinical Trial Of TN-301, A Highly Selective HDAC6 Inhibitor With Potential In HFPEF, Shows Target Engagement

被引：0
|
作者：
Bexon, Martin [1 ]
Argast, Gretchen [1 ]
Robertson, Laura [1 ]
Hoey, Timothy [1 ]
Vora, Jay [1 ]
Tingley, Whittemore [2 ]
Browns, Fran [3 ]
Schmelzer, Kara [3 ]
机构：
[1] Tenaya Therapeut, San Francisco, CA USA
[2] Nayath Erapeut, Berkeley, CA USA
[3] Certara, Princeton, NJ USA
来源：
JOURNAL OF CARDIAC FAILURE | 2024年 / 30卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
417
引用
收藏
页码：295 / 295
页数：1
相关论文
共 13 条
  • [1] Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma
    Yee, Andrew J.
    Voorhees, Peter M.
    Bensinger, William
    Berdeja, Jesus G.
    Supko, Jeffrey G.
    Richardson, Paul G.
    Tamang, David
    Jones, Simon S.
    Patrick, Gretchen
    Wheeler, Catherine
    Raje, Noopur
    BLOOD, 2014, 124 (21)
  • [2] RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS
    Raje, N.
    Bensinger, W.
    Lebovic, D.
    Lonial, S.
    Jagannath, S.
    Acre-Lara, C.
    Rosko, A.
    Harb, W.
    Bahlis, N.
    Supko, J.
    Tamang, D.
    Jones, S.
    Wheeler, C.
    Richardson, P.
    HAEMATOLOGICA, 2015, 100 : 86 - 86
  • [3] RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HDAC6 INHIBITOR, COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE SHOWS PROMISING EARLY PHASE 2 RESULTS IN RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: ACE-MM-102
    Raje, N.
    Terpos, E.
    Cole, C.
    Bahlis, N.
    Bensinger, W.
    Libby, E.
    Palumbo, A.
    Lonial, S.
    Sandhu, I.
    Arce-Lara, C.
    Jagannath, S.
    Valent, J.
    Rosko, A.
    Reece, D.
    Supko, J.
    Tamang, D.
    Jones, S.
    Wheeler, C.
    Markelewicz, R.
    Richardson, P.
    HAEMATOLOGICA, 2016, 101 : 328 - 328
  • [4] PLN-74809, a Dual-Selective Inhibitor of Integrins αvβ6 and αvβ1, Shows Dose-Dependent Target Engagement in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Mooney, J. J.
    Morris, K.
    Jacobs, S.
    Lefebvre, E.
    Cosgrove, G. P.
    Wong, S.
    Bellini, J.
    Jurek, M.
    Turner, S.
    Decaris, M.
    Jiron, R.
    Williams, B.
    Duan, H.
    Gunn, R.
    Rizzo, G.
    Wardak, M.
    Guo, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [5] Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)
    Vogl, Dan T.
    Raje, Noopur S.
    Jagannath, Sundar
    Richardson, Paul G.
    Hari, Parameswaran
    Orlowski, Robert Z.
    Supko, Jeffrey
    Tamang, David
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J., Jr.
    Lonial, Sagar
    BLOOD, 2015, 126 (23)
  • [6] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
    Yan Zhao
    Litao Zhang
    Yangfeng Ding
    Xiaohua Tao
    Chao Ji
    Xiuqin Dong
    Jianyun Lu
    Liming Wu
    Rupeng Wang
    Qianjin Lu
    Aik Han Goh
    Rongjun Liu
    Zhiguo Zhang
    Jianzhong Zhang
    American Journal of Clinical Dermatology, 2021, 22 : 877 - 889
  • [7] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
    Zhao, Yan
    Zhang, Litao
    Ding, Yangfeng
    Tao, Xiaohua
    Ji, Chao
    Dong, Xiuqin
    Lu, Jianyun
    Wu, Liming
    Wang, Rupeng
    Lu, Qianjin
    Goh, Aik Han
    Liu, Rongjun
    Zhang, Zhiguo
    Zhang, Jianzhong
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (06) : 877 - 889
  • [8] Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial
    Westlin, William F.
    Stiede, Kathryn
    Lounsbury, Heather
    Witowski, Steve
    Silver, Bruce
    Freed, Martin
    Mahadevan, Daruka
    Sharman, Jeff
    Harb, Wael A.
    Petter, Russell
    Singh, Juswinder
    Evans, Erica
    CANCER RESEARCH, 2012, 72
  • [9] Preclinical evaluation of LYS6K1, a novel, highly selective, orally bioavailable inhibitor of p70 S6 kinase currently in phase I clinical trials for cancer
    Geeganage, Sandaruwan
    Sams, Lillian L.
    Joseph, Sajan
    Brail, Leslie
    Wang, Tao
    Rodgers, George
    Akunda, Jackie
    Huang, Jianping
    Perkins, Everett J.
    Ajamie, Rose
    CANCER RESEARCH, 2010, 70
  • [10] Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer
    Geeganage, S.
    Sams, L.
    Joseph, S.
    Shepherd, T.
    Dally, R.
    Brail, L.
    Wang, T.
    Capen, A.
    Rodgers, G.
    Perkins, E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 28 - 28
12